- Home
- CHRO vs PPBT Comparison
CHRO vs PPBT Comparison
Compare CHRO & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRO
- PPBT
- Stock Information
- Founded
- CHRO 2002
- PPBT 2010
- Country
- CHRO United States
- PPBT Israel
- Employees
- CHRO N/A
- PPBT N/A
- Industry
- CHRO
- PPBT Biotechnology: Pharmaceutical Preparations
- Sector
- CHRO
- PPBT Health Care
- Exchange
- CHRO Nasdaq
- PPBT Nasdaq
- Market Cap
- CHRO 7.6M
- PPBT 6.3M
- IPO Year
- CHRO 2024
- PPBT N/A
- Fundamental
- Price
- CHRO $1.35
- PPBT $2.34
- Analyst Decision
- CHRO
- PPBT Strong Buy
- Analyst Count
- CHRO 0
- PPBT 1
- Target Price
- CHRO N/A
- PPBT $33.00
- AVG Volume (30 Days)
- CHRO 135.3K
- PPBT 29.4K
- Earning Date
- CHRO 08-12-2025
- PPBT 08-15-2025
- Dividend Yield
- CHRO N/A
- PPBT N/A
- EPS Growth
- CHRO N/A
- PPBT N/A
- EPS
- CHRO N/A
- PPBT N/A
- Revenue
- CHRO N/A
- PPBT N/A
- Revenue This Year
- CHRO N/A
- PPBT N/A
- Revenue Next Year
- CHRO N/A
- PPBT N/A
- P/E Ratio
- CHRO N/A
- PPBT N/A
- Revenue Growth
- CHRO N/A
- PPBT N/A
- 52 Week Low
- CHRO $0.45
- PPBT $2.00
- 52 Week High
- CHRO $3.80
- PPBT $13.95
- Technical
- Relative Strength Index (RSI)
- CHRO 63.60
- PPBT 41.27
- Support Level
- CHRO $1.12
- PPBT $2.30
- Resistance Level
- CHRO $1.23
- PPBT $2.45
- Average True Range (ATR)
- CHRO 0.16
- PPBT 0.14
- MACD
- CHRO 0.01
- PPBT -0.03
- Stochastic Oscillator
- CHRO 30.26
- PPBT 16.58
About CHRO Chromocell Therapeutics Corporation
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic, visceral pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.